Weight Loss Medication During Menopause

For adult weight management, clinicians generally consider medication at a BMI of at least 30, or at least 27 with a weight-related condition such as high blood pressure or type 2 diabetes. These criteria are a starting point. The clinician also checks the specific indication, likely benefit, contraindications, and your treatment goals.

Bring the history of your weight and previous attempts to manage it. Explain whether the main concern is glucose, blood pressure, sleep apnea, pain, or difficulty maintaining a previous loss. Include appetite, eating difficulties, medication changes, and symptoms that make activity harder.

The assessment may include height, weight, blood pressure, relevant blood tests, and a medication review. Thyroid disease, sleep problems, and medicines associated with weight gain may need attention. Menopause-related heat or insomnia can be treated alongside weight care.

Product labels and availability change. Ask which medicine fits your conditions and why it is being recommended, and review its full prescribing instructions. Semaglutide and tirzepatide should not be combined with another GLP-1 medicine.

For Wegovy and Zepbound, a personal or family history of medullary thyroid cancer or MEN 2 is a contraindication. Their boxed warnings describe thyroid C-cell tumors in rodents; whether this occurs in humans is unknown. Tell the clinician which thyroid condition is in your history so it can be interpreted accurately.

Discuss previous pancreatitis, gallbladder problems, severe stomach-emptying problems, kidney disease, diabetic eye disease, and allergic reactions. Insulin or a sulfonylurea may need adjustment because low blood glucose becomes more likely when combined with these treatments. The prescriber should provide a monitoring plan.

Both medicines delay stomach emptying and can affect oral medication. Bring the full list, including hormones, thyroid tablets, and supplements. Tell surgical and anesthesia teams about treatment before a procedure because the labels include a warning about aspiration during anesthesia or deep sedation.

Irregular periods do not rule out ovulation. Weight loss medication should not be used during pregnancy or when planning pregnancy. Discuss contraception and a stopping plan before treatment. Menopause hormone therapy does not prevent pregnancy.

For weight treatment, Wegovy should be stopped at least two months before a planned pregnancy. Zepbound's label advises stopping when pregnancy is recognized and requires a separate contraceptive precaution: oral hormonal contraception may be less effective. Use a nonoral method or add a barrier method for four weeks after starting and four weeks after each dose increase, following the prescriber's advice.

Lower appetite can make portions much smaller. Include protein foods and enough overall nutrition, and tell the prescriber if nausea, vomiting, or low appetite makes eating or drinking difficult. A dietitian can help adapt meals without making the plan excessively restrictive.

Strength work helps keep physical function in the review. Adult guidance recommends two or more days of muscle-strengthening activity each week alongside aerobic activity. Begin at a suitable level and record changes in strength or daily tasks as well as weight.

Digestive effects are common with Wegovy and Zepbound, especially around dose changes. A dose increase should follow the prescribed schedule and your tolerance. Persistent vomiting, dehydration, severe abdominal pain, or a marked decline in intake requires contact with the clinical team.

Many weight medicines are used long term when they continue to help and remain tolerable. Weight regain can occur after stopping. Agree on review intervals, the outcomes being monitored, and what happens if treatment needs to change or access is interrupted.

Ask for the medicine name, formulation, pharmacy, and written dose instructions. Compounded products do not undergo FDA review for safety, effectiveness, and quality. FDA has reported dosing errors and concerns about semaglutide salt forms. If compounding is proposed, ask why an approved medicine cannot meet the medical need.

• Confirm medication cost separately from appointments, laboratory work, and any supplies.
• Ask how dose changes and side-effect messages will be handled.
• Review blood pressure or glucose when those conditions prompted treatment.
• Agree on nutrition, activity, and follow-up that can continue as weight changes.